argenx SE or United Therapeutics Corporation: Who Leads in Yearly Revenue?

Argenx SE vs. United Therapeutics: A Revenue Showdown

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, United Therapeutics Corporation has consistently outpaced Argenx SE in annual revenue. From 2014 to 2023, United Therapeutics saw a steady increase, culminating in a 44% rise from 2014 to 2023. In contrast, Argenx SE, while starting from a modest base, experienced a remarkable surge, especially in recent years, with a staggering 2,600% increase over the same period.

A Decade of Growth

United Therapeutics maintained a strong revenue stream, peaking at $2.3 billion in 2023. Meanwhile, Argenx SE's revenue skyrocketed, reaching $1.2 billion in 2023, a testament to its rapid expansion and market penetration. This data highlights the dynamic nature of the biotech industry, where innovation and strategic growth can lead to significant financial gains.